Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment.

ABSTRACT:

Background

Angiotensin receptor-neprilysin inhibitors (ARNIs) could improve the outcome of patients with hypertension or heart failure. Yet it remains unclear if such protective effect exists in lung cancer patients with hypertension undergoing immune checkpoint inhibitors (ICIs).

Objective

This study sought to evaluate the impact of ARNIs on the outcome of lung cancer patients with hypertension treated with ICIs.

Methods

We performed a retrospective analysis of lung cancer patients with concurrent hypertension undergoing ICIs treatment between September 2019 and May 2024 in Shanghai Chest Hospital. The overall population included patients with or without ARNIs therapy. The primary endpoint was all-cause mortality and the secondary endpoint was a composite of cardiova

SUBMITTER: Shang C 

PROVIDER: S-EPMC12771887 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature